Bismuth valproate API was developed at Minakem’s Canadian facility (Delmar Chemicals) in 2016. Bismuth valproate API CAS number is 60364-28-5.
From a regulatory perspective, Minakem offers:
– A Canadian DMF (Drug Master File)
Therapeutical Class and Mechanism of Action
Bismuth valproate API is used in Canada in over-the-counter medication to treat NeoLaryngobis.
The mechanism of action of valproate drugs involves enhancing inhibitory neurotransmission and modulating voltage-gated ion channels.
About Minakem Montreal’s Expertise
Minakem Montreal (Delmar chemicals Inc.) has been manufacturing Active Pharmaceutical Ingredients (APIs) since 1941. It is the largest API facility in Canada, benefiting from a strong scientific and technological environment. Located close to its U.S. customers in the New Jersey and Boston areas, Montreal also has a strong tradition of serving the entire North American market, as well as Latin America, Europe, Japan, China, and India.
About Minakem’s Network
Minakem Montreal works daily with Minakem’s other European facilities, leveraging their complementary expertise, such as solid engineering, analytics, global regulatory affairs, and capabilities to optimize competitiveness.
Minakem has over 40 years of expertise in developing, scaling up, registering DMFs, and manufacturing complex APIs, including chiral small molecules, steroids, and highly potent APIs (HPAPIs, primarily used in oncology treatments).
Strong supply chain performance is becoming critical to our customers’ success.
Minakem’s operations focus on producing safe products for patients, achieving high OTIF performance, providing strong quality support, and consistently seeking solutions to meet customers’ unexpected market demands.
More data on Bismuth valproate API
Bismuth valproate’s data are available on Pharmaoffer.
Bismuth valproate additional data are available on Wikipedia
-
Category
-
CAS NO.
60364-28-5
-
Certificates
GMP
-
Structure
